论文部分内容阅读
[目的]探讨舒肝解郁胶囊联合莫沙比利治疗慢传输型便秘(STC)的临床疗效和安全性。[方法]84例符合罗马Ⅲ诊断标准的STC患者随机分为试验组与对照组;试验组42例使用舒肝解郁胶囊联合莫沙比利治疗,对照组42例单用莫沙比利,疗程均为6周;采用便秘症状评分、Zung抑郁自评量表(SDS)、Zung焦虑自评量表(SAS)评定2组疗效。[结果]治疗前、治疗3周末、治疗6周末,试验组便秘症状总分分别为(13.87±3.11)分、(9.61±2.32)分、(4.01±2.17)分,组内比较差异均有统计学意义(P<0.05);对照组便秘症状总分分别为(13.02±2.90)分、(10.08±2.11)分、(9.54±2.01)分,治疗6周末与治疗前比较差异有统计学意义(P<0.05);试验组与对照组治疗6周末比较差异有统计学意义(P<0.05)。治疗前、治疗3周末、治疗6周末试验组SDS和SAS评分分别为(52.14±6.37)分、(48.10±7.01)分、(46.32±8.21)分和(48.17±7.78)分、(43.38±6.89)分、(40.18±9.97)分,差异均有统计学意义(P<0.05);对照组分别为(51.87±5.89)分、(51.64±8.31)分、(49.57±6.07)分和(47.05±8.40)分、(45.92±8.98)分、(44.78±7.30)分,差异均无统计学意义(P>0.05);治疗6周末2组SDS和SAS评分比较差异均有统计学意义(P<0.05)。[结论]舒肝解郁胶囊能有效改善STC患者的焦虑抑郁情绪,足疗程舒肝解郁胶囊与莫沙比利联合使用治疗STC的临床疗效优于单用莫沙比利。
[Objective] To investigate the clinical efficacy and safety of Shugan Jieyu capsule combined with Mosapride in the treatment of slow transit constipation (STC). [Method] Eighty-four STC patients meeting the diagnostic criteria of Rome Ⅲ were randomly divided into experimental group and control group. In the experimental group, 42 cases were treated with Shugan Jieyu capsules combined with mosapride, 42 cases in the control group were treated with mosapride, The course of treatment was 6 weeks. The symptoms of constipation, Zung depression self-rating scale (SDS) and Zung self-rating anxiety scale (SAS) were used to evaluate the efficacy of the two groups. [Results] The scores of constipation before treatment, 3 weeks after treatment and 6 weeks after treatment were (13.87 ± 3.11) points (9.61 ± 2.32) and (4.01 ± 2.17) points, respectively (P0.05) .Conclusion The total scores of constipation in the control group were (13.02 ± 2.90), (10.08 ± 2.11) and (9.54 ± 2.01) points respectively. There was significant difference between the two groups P <0.05). There was significant difference between the experimental group and the control group at the end of 6th week (P <0.05). The score of SDS and SAS before treatment, 3 weeks after treatment and 6 weeks after treatment were (52.14 ± 6.37), (48.10 ± 7.01), (46.32 ± 8.21) and (48.17 ± 7.78), (43.38 ± 6.89) (51.18 ± 5.89), (51.64 ± 8.31) points, (49.57 ± 6.07) points and (47.05 ±) points respectively, the difference was statistically significant (P <0.05) 8.40), (45.92 ± 8.98) points and (44.78 ± 7.30) points respectively. There was no significant difference between the two groups (P> 0.05) ). [Conclusion] Shugan Jieyu Capsule can effectively improve anxiety and depression in patients with STC. The clinical efficacy of Shugan Jieyu Capsule combined with mosapride in treating STC is superior to that of mosapride alone.